CULLINAN THERAPEUTICS INC (CGEM) Fundamental Analysis & Valuation

NASDAQ:CGEM • US2300311063

Current stock price

14.4799 USD
-0.06 (-0.41%)
Last:

This CGEM fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. CGEM Profitability Analysis

1.1 Basic Checks

  • In the past year CGEM has reported negative net income.
  • In the past year CGEM has reported a negative cash flow from operations.
  • In the past 5 years CGEM reported 4 times negative net income.
  • In the past 5 years CGEM always reported negative operating cash flow.
CGEM Yearly Net Income VS EBIT VS OCF VS FCFCGEM Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 2025 0 100M -100M

1.2 Ratios

  • CGEM's Return On Assets of -49.04% is in line compared to the rest of the industry. CGEM outperforms 47.09% of its industry peers.
  • Looking at the Return On Equity, with a value of -53.80%, CGEM is in the better half of the industry, outperforming 61.24% of the companies in the same industry.
Industry RankSector Rank
ROA -49.04%
ROE -53.8%
ROIC N/A
ROA(3y)-12.91%
ROA(5y)-15.57%
ROE(3y)-13.78%
ROE(5y)-16.56%
ROIC(3y)N/A
ROIC(5y)N/A
CGEM Yearly ROA, ROE, ROICCGEM Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 2025 0 20 -20 -40

1.3 Margins

  • CGEM does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CGEM Yearly Profit, Operating, Gross MarginsCGEM Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. CGEM Health Analysis

2.1 Basic Checks

  • The number of shares outstanding for CGEM has been increased compared to 1 year ago.
  • Compared to 5 years ago, CGEM has more shares outstanding
  • There is no outstanding debt for CGEM. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
CGEM Yearly Shares OutstandingCGEM Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M
CGEM Yearly Total Debt VS Total AssetsCGEM Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M

2.2 Solvency

  • CGEM has an Altman-Z score of 10.64. This indicates that CGEM is financially healthy and has little risk of bankruptcy at the moment.
  • CGEM has a better Altman-Z score (10.64) than 82.17% of its industry peers.
  • CGEM has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 10.64
ROIC/WACCN/A
WACCN/A
CGEM Yearly LT Debt VS Equity VS FCFCGEM Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 2025 0 200M 400M

2.3 Liquidity

  • A Current Ratio of 10.25 indicates that CGEM has no problem at all paying its short term obligations.
  • The Current ratio of CGEM (10.25) is better than 80.23% of its industry peers.
  • A Quick Ratio of 10.25 indicates that CGEM has no problem at all paying its short term obligations.
  • CGEM has a better Quick ratio (10.25) than 80.23% of its industry peers.
Industry RankSector Rank
Current Ratio 10.25
Quick Ratio 10.25
CGEM Yearly Current Assets VS Current LiabilitesCGEM Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M 400M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

0

3. CGEM Growth Analysis

3.1 Past

  • The earnings per share for CGEM have decreased strongly by -10.56% in the last year.
EPS 1Y (TTM)-10.56%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-5.48%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • Based on estimates for the next years, CGEM will show a small growth in Earnings Per Share. The EPS will grow by 2.90% on average per year.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y10.01%
EPS Next 2Y6.42%
EPS Next 3Y5.22%
EPS Next 5Y2.9%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
CGEM Yearly Revenue VS EstimatesCGEM Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2026 2027 2028 2029 2030 2031 200M 400M 600M
CGEM Yearly EPS VS EstimatesCGEM Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 2 -2 -4

More info and screens

Find the best growth stocksShow best growing peers

0

4. CGEM Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for CGEM. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CGEM. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CGEM Price Earnings VS Forward Price EarningsCGEM Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CGEM Per share dataCGEM EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 6

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y6.42%
EPS Next 3Y5.22%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. CGEM Dividend Analysis

5.1 Amount

  • CGEM does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

CGEM Fundamentals: All Metrics, Ratios and Statistics

CULLINAN THERAPEUTICS INC

NASDAQ:CGEM (4/13/2026, 12:19:35 PM)

14.4799

-0.06 (-0.41%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-10
Earnings (Next)05-07
Inst Owners105.08%
Inst Owner Change0%
Ins Owners1.15%
Ins Owner Change0.13%
Market Cap876.47M
Revenue(TTM)N/A
Net Income(TTM)-219.88M
Analysts88.42
Price Target34.42 (137.71%)
Short Float %14.1%
Short Ratio10.37
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)13.94%
Min EPS beat(2)6.74%
Max EPS beat(2)21.14%
EPS beat(4)3
Avg EPS beat(4)2.85%
Min EPS beat(4)-25.93%
Max EPS beat(4)21.14%
EPS beat(8)6
Avg EPS beat(8)5.81%
EPS beat(12)9
Avg EPS beat(12)5.81%
EPS beat(16)12
Avg EPS beat(16)9.55%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)4.38%
PT rev (3m)4.81%
EPS NQ rev (1m)4.97%
EPS NQ rev (3m)2.16%
EPS NY rev (1m)-0.79%
EPS NY rev (3m)-0.82%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 2.14
P/tB 2.14
EV/EBITDA N/A
EPS(TTM)-3.35
EYN/A
EPS(NY)-3.01
Fwd EYN/A
FCF(TTM)-2.4
FCFYN/A
OCF(TTM)-2.4
OCFYN/A
SpS0
BVpS6.75
TBVpS6.75
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -49.04%
ROE -53.8%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-12.91%
ROA(5y)-15.57%
ROE(3y)-13.78%
ROE(5y)-16.56%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 0%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 10.25
Quick Ratio 10.25
Altman-Z 10.64
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)440.88%
Cap/Depr(5y)267.86%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-10.56%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-5.48%
EPS Next Y10.01%
EPS Next 2Y6.42%
EPS Next 3Y5.22%
EPS Next 5Y2.9%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-22.71%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-19.16%
EBIT Next 3Y-3.25%
EBIT Next 5Y-8.39%
FCF growth 1Y-8.05%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-8.21%
OCF growth 3YN/A
OCF growth 5YN/A

CULLINAN THERAPEUTICS INC / CGEM Fundamental Analysis FAQ

What is the fundamental rating for CGEM stock?

ChartMill assigns a fundamental rating of 3 / 10 to CGEM.


What is the valuation status for CGEM stock?

ChartMill assigns a valuation rating of 0 / 10 to CULLINAN THERAPEUTICS INC (CGEM). This can be considered as Overvalued.


What is the profitability of CGEM stock?

CULLINAN THERAPEUTICS INC (CGEM) has a profitability rating of 1 / 10.


What is the expected EPS growth for CULLINAN THERAPEUTICS INC (CGEM) stock?

The Earnings per Share (EPS) of CULLINAN THERAPEUTICS INC (CGEM) is expected to grow by 10.01% in the next year.